Expedeon Aktie

Expedeon für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A1RFM0 / ISIN: DE000A1RFM03

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
20.06.2016 19:30:01

DGAP-News: SYGNIS AG

DGAP-News: SYGNIS AG announces outcome of Annual General Meeting 2016

DGAP-News: SYGNIS AG / Key word(s): AGM/EGM SYGNIS AG announces outcome of Annual General Meeting 2016

20.06.2016 / 19:30 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Press Release

SYGNIS AG announces outcome of Annual General Meeting 2016

- Shareholders approve all management proposals put to vote at the meeting

- Acquisition of Expedeon to proceed as expected



Madrid, Spain and Heidelberg, Germany, 20 June 2016 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) announced today that the Annual General Meeting (AGM) held in Wiesloch today on 20 June 2016 voted in favour of all Management proposals put to vote. Participating shareholders representing 44 percent of the entire share capital of 16.8 million shares approved all proposals of the Management with a large majority. The main decision was related to the planned acquisition of Expedeon Holdings Ltd. that was announced on 9 May 2016. To finance the transaction, the AGM approved that the Company's share capital will be increased by up to EUR 20,538,089.00 from EUR 16,803,891.00 to EUR 37,341,980.00 by issuing up to 20,538,089 shares by way of a rights offering. In addition, the AGM approved that Tim McCarthy and Trevor Jarman, previously member of the Board of Directors, respectively Chairman of the Board of Directors of Expedeon, were appointed as new Supervisory Board members of SYGNIS, while Friedrich von Bohlen und Halbach, PhD, and Pedro-Agustín del Castillo Machado have left the Supervisory Board; Chairwoman Cristina Garmendia Mendizábal thanked them for their collaboration during the last years. Further decisions at the AGM were the discharge of the members of the Supervisory and the Management Board for the past fiscal year, the creation of new authorized capital, as well as changes due to the authorization the Management Board to issue convertible bonds, excluding subscription rights, among others. "On behalf of the Management Board and the Company, I would like to thank our shareholders for their continued support and trust. We are very happy that our shareholders support the acquisition of Expedeon. Today's vote confirms the confidence of shareholders in the SYGNIS management and the ongoing transaction. We are now able to start with the capital increase process," Pilar de la Huerta, CEO and CFO of SYGNIS commented. "Expedeon is an excellent target for us as they have a strong management, an international sales force, a good sales presence and also manufacturing sites in the UK and the US. In addition, their product portfolio complements ours perfectly. Together with Expedeon's CEO, Heikki Lanckriet we are looking forward to join forces and to become a leading player in the genomics and proteomics markets."

For further information please contact:

SYGNIS AG MC Services AG Pilar de la Huerta Raimund Gabriel CEO/CFO Managing Partner Phone: +34 91 192 36 50 Phone: +49 89 210228 30 Email: pdelahuerta@sygnis.com Email: raimund.gabriel@mc-services.eu

About SYGNIS AG: www.sygnis.com

SYGNIS, headquartered in Germany and Spain, specializes in the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast-growing fields of molecular biology and next-generation sequencing applications. Key products include the TruePrime(TM) product line and SensiPhi(R), licensed to a leading industry partner, for whole genome DNA amplification and sequencing, as well as the SunScript(TM) Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed on the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward- looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###

---------------------------------------------------------------------------

20.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English Company: SYGNIS AG Waldhofer Str. 104 69123 Heidelberg Germany Phone: +49 (0) 6221 3540 125 Fax: +49 (0) 6221 3540 127 E-mail: investors@sygnis.com Internet: www.sygnis.com ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News Service ---------------------------------------------------------------------------

472939 20.06.2016

Nachrichten zu Expedeon (ex Sygnis)mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Expedeon (ex Sygnis)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!